nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—Melaena—Alendronate—Paget's disease of bone	0.00814	0.00822	CcSEcCtD
Erlotinib—Rigors—Pamidronate—Paget's disease of bone	0.00779	0.00786	CcSEcCtD
Erlotinib—Cardiovascular disorder—Risedronate—Paget's disease of bone	0.00761	0.00769	CcSEcCtD
Erlotinib—Myalgia—Tiludronate—Paget's disease of bone	0.0076	0.00768	CcSEcCtD
Erlotinib—Arthralgia—Tiludronate—Paget's disease of bone	0.0076	0.00768	CcSEcCtD
Erlotinib—Rigors—Zoledronate—Paget's disease of bone	0.00711	0.00718	CcSEcCtD
Erlotinib—Bone pain—Risedronate—Paget's disease of bone	0.00698	0.00705	CcSEcCtD
Erlotinib—Inflammation—Risedronate—Paget's disease of bone	0.00689	0.00696	CcSEcCtD
Erlotinib—Musculoskeletal pain—Risedronate—Paget's disease of bone	0.00677	0.00684	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Tiludronate—Paget's disease of bone	0.00664	0.0067	CcSEcCtD
Erlotinib—Bone pain—Pamidronate—Paget's disease of bone	0.00664	0.0067	CcSEcCtD
Erlotinib—Proteinuria—Zoledronate—Paget's disease of bone	0.00661	0.00667	CcSEcCtD
Erlotinib—Inflammation—Pamidronate—Paget's disease of bone	0.00655	0.00662	CcSEcCtD
Erlotinib—Protein urine present—Zoledronate—Paget's disease of bone	0.00652	0.00658	CcSEcCtD
Erlotinib—Musculoskeletal pain—Pamidronate—Paget's disease of bone	0.00643	0.0065	CcSEcCtD
Erlotinib—Colitis—Risedronate—Paget's disease of bone	0.00642	0.00648	CcSEcCtD
Erlotinib—Dyspepsia—Tiludronate—Paget's disease of bone	0.00641	0.00648	CcSEcCtD
Erlotinib—Gastritis—Etidronic acid—Paget's disease of bone	0.00628	0.00635	CcSEcCtD
Erlotinib—Pain—Tiludronate—Paget's disease of bone	0.00623	0.00629	CcSEcCtD
Erlotinib—Dry eye—Risedronate—Paget's disease of bone	0.00618	0.00624	CcSEcCtD
Erlotinib—Bone pain—Zoledronate—Paget's disease of bone	0.00606	0.00612	CcSEcCtD
Erlotinib—Inflammation—Zoledronate—Paget's disease of bone	0.00599	0.00605	CcSEcCtD
Erlotinib—Gastrointestinal pain—Tiludronate—Paget's disease of bone	0.00596	0.00602	CcSEcCtD
Erlotinib—Musculoskeletal pain—Zoledronate—Paget's disease of bone	0.00588	0.00594	CcSEcCtD
Erlotinib—Abdominal pain—Tiludronate—Paget's disease of bone	0.00576	0.00582	CcSEcCtD
Erlotinib—Dry skin—Alendronate—Paget's disease of bone	0.00554	0.0056	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Alendronate—Paget's disease of bone	0.00545	0.0055	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Etidronic acid—Paget's disease of bone	0.00542	0.00548	CcSEcCtD
Erlotinib—Neuropathy peripheral—Etidronic acid—Paget's disease of bone	0.00536	0.00542	CcSEcCtD
Erlotinib—Gastritis—Alendronate—Paget's disease of bone	0.00535	0.00541	CcSEcCtD
Erlotinib—Dysphagia—Alendronate—Paget's disease of bone	0.00523	0.00528	CcSEcCtD
Erlotinib—Asthenia—Tiludronate—Paget's disease of bone	0.00523	0.00528	CcSEcCtD
Erlotinib—Renal failure acute—Pamidronate—Paget's disease of bone	0.005	0.00505	CcSEcCtD
Erlotinib—Diarrhoea—Tiludronate—Paget's disease of bone	0.00499	0.00504	CcSEcCtD
Erlotinib—Dizziness—Tiludronate—Paget's disease of bone	0.00482	0.00487	CcSEcCtD
Erlotinib—Erythema multiforme—Etidronic acid—Paget's disease of bone	0.00464	0.00469	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Alendronate—Paget's disease of bone	0.00462	0.00467	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Pamidronate—Paget's disease of bone	0.00461	0.00466	CcSEcCtD
Erlotinib—Renal failure acute—Zoledronate—Paget's disease of bone	0.00457	0.00461	CcSEcCtD
Erlotinib—Headache—Tiludronate—Paget's disease of bone	0.00456	0.00461	CcSEcCtD
Erlotinib—Stomatitis—Alendronate—Paget's disease of bone	0.00454	0.00459	CcSEcCtD
Erlotinib—Renal impairment—Zoledronate—Paget's disease of bone	0.00443	0.00447	CcSEcCtD
Erlotinib—Alopecia—Etidronic acid—Paget's disease of bone	0.00434	0.00438	CcSEcCtD
Erlotinib—Nausea—Tiludronate—Paget's disease of bone	0.00433	0.00437	CcSEcCtD
Erlotinib—Gastritis—Risedronate—Paget's disease of bone	0.0043	0.00434	CcSEcCtD
Erlotinib—Erythema—Etidronic acid—Paget's disease of bone	0.00428	0.00432	CcSEcCtD
Erlotinib—Flatulence—Etidronic acid—Paget's disease of bone	0.00421	0.00426	CcSEcCtD
Erlotinib—Haemoglobin—Alendronate—Paget's disease of bone	0.00421	0.00425	CcSEcCtD
Erlotinib—Hypokalaemia—Pamidronate—Paget's disease of bone	0.0042	0.00424	CcSEcCtD
Erlotinib—Haemorrhage—Alendronate—Paget's disease of bone	0.00419	0.00423	CcSEcCtD
Erlotinib—Gastritis—Pamidronate—Paget's disease of bone	0.00408	0.00412	CcSEcCtD
Erlotinib—Erythema multiforme—Alendronate—Paget's disease of bone	0.00396	0.004	CcSEcCtD
Erlotinib—Dehydration—Zoledronate—Paget's disease of bone	0.00392	0.00396	CcSEcCtD
Erlotinib—Hypokalaemia—Zoledronate—Paget's disease of bone	0.00384	0.00387	CcSEcCtD
Erlotinib—Pneumonia—Risedronate—Paget's disease of bone	0.00376	0.0038	CcSEcCtD
Erlotinib—Infestation NOS—Risedronate—Paget's disease of bone	0.00374	0.00378	CcSEcCtD
Erlotinib—Infestation—Risedronate—Paget's disease of bone	0.00374	0.00378	CcSEcCtD
Erlotinib—Gastritis—Zoledronate—Paget's disease of bone	0.00373	0.00377	CcSEcCtD
Erlotinib—Depression—Risedronate—Paget's disease of bone	0.00373	0.00377	CcSEcCtD
Erlotinib—Neutropenia—Pamidronate—Paget's disease of bone	0.00373	0.00377	CcSEcCtD
Erlotinib—Alopecia—Alendronate—Paget's disease of bone	0.0037	0.00374	CcSEcCtD
Erlotinib—Erythema—Alendronate—Paget's disease of bone	0.00364	0.00368	CcSEcCtD
Erlotinib—Dysphagia—Zoledronate—Paget's disease of bone	0.00364	0.00368	CcSEcCtD
Erlotinib—Arthralgia—Etidronic acid—Paget's disease of bone	0.00364	0.00368	CcSEcCtD
Erlotinib—Conjunctivitis—Risedronate—Paget's disease of bone	0.00364	0.00367	CcSEcCtD
Erlotinib—Flatulence—Alendronate—Paget's disease of bone	0.00359	0.00363	CcSEcCtD
Erlotinib—Pneumonia—Pamidronate—Paget's disease of bone	0.00358	0.00361	CcSEcCtD
Erlotinib—Infestation NOS—Pamidronate—Paget's disease of bone	0.00356	0.00359	CcSEcCtD
Erlotinib—Infestation—Pamidronate—Paget's disease of bone	0.00356	0.00359	CcSEcCtD
Erlotinib—Hepatobiliary disease—Risedronate—Paget's disease of bone	0.00354	0.00357	CcSEcCtD
Erlotinib—Renal failure—Pamidronate—Paget's disease of bone	0.0035	0.00353	CcSEcCtD
Erlotinib—Infection—Etidronic acid—Paget's disease of bone	0.00347	0.0035	CcSEcCtD
Erlotinib—Stomatitis—Pamidronate—Paget's disease of bone	0.00347	0.0035	CcSEcCtD
Erlotinib—Conjunctivitis—Pamidronate—Paget's disease of bone	0.00346	0.00349	CcSEcCtD
Erlotinib—Neutropenia—Zoledronate—Paget's disease of bone	0.00341	0.00344	CcSEcCtD
Erlotinib—Haemoglobin—Risedronate—Paget's disease of bone	0.00337	0.00341	CcSEcCtD
Erlotinib—Haemorrhage—Risedronate—Paget's disease of bone	0.00336	0.00339	CcSEcCtD
Erlotinib—Urinary tract disorder—Risedronate—Paget's disease of bone	0.00332	0.00335	CcSEcCtD
Erlotinib—Connective tissue disorder—Risedronate—Paget's disease of bone	0.0033	0.00333	CcSEcCtD
Erlotinib—Weight decreased—Zoledronate—Paget's disease of bone	0.0033	0.00333	CcSEcCtD
Erlotinib—Urethral disorder—Risedronate—Paget's disease of bone	0.00329	0.00332	CcSEcCtD
Erlotinib—Infestation NOS—Zoledronate—Paget's disease of bone	0.00325	0.00328	CcSEcCtD
Erlotinib—Infestation—Zoledronate—Paget's disease of bone	0.00325	0.00328	CcSEcCtD
Erlotinib—Depression—Zoledronate—Paget's disease of bone	0.00324	0.00327	CcSEcCtD
Erlotinib—Haemoglobin—Pamidronate—Paget's disease of bone	0.00321	0.00324	CcSEcCtD
Erlotinib—Renal failure—Zoledronate—Paget's disease of bone	0.00319	0.00322	CcSEcCtD
Erlotinib—Haemorrhage—Pamidronate—Paget's disease of bone	0.00319	0.00322	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Etidronic acid—Paget's disease of bone	0.00318	0.00321	CcSEcCtD
Erlotinib—Stomatitis—Zoledronate—Paget's disease of bone	0.00317	0.0032	CcSEcCtD
Erlotinib—Conjunctivitis—Zoledronate—Paget's disease of bone	0.00316	0.00319	CcSEcCtD
Erlotinib—Urinary tract disorder—Pamidronate—Paget's disease of bone	0.00315	0.00318	CcSEcCtD
Erlotinib—Eye disorder—Risedronate—Paget's disease of bone	0.00314	0.00317	CcSEcCtD
Erlotinib—Connective tissue disorder—Pamidronate—Paget's disease of bone	0.00314	0.00317	CcSEcCtD
Erlotinib—Urethral disorder—Pamidronate—Paget's disease of bone	0.00313	0.00316	CcSEcCtD
Erlotinib—Chest pain—Alendronate—Paget's disease of bone	0.0031	0.00313	CcSEcCtD
Erlotinib—Myalgia—Alendronate—Paget's disease of bone	0.0031	0.00313	CcSEcCtD
Erlotinib—Dyspepsia—Etidronic acid—Paget's disease of bone	0.00307	0.0031	CcSEcCtD
Erlotinib—Mediastinal disorder—Risedronate—Paget's disease of bone	0.00303	0.00306	CcSEcCtD
Erlotinib—Arrhythmia—Risedronate—Paget's disease of bone	0.003	0.00303	CcSEcCtD
Erlotinib—Constipation—Etidronic acid—Paget's disease of bone	0.00298	0.00301	CcSEcCtD
Erlotinib—Eye disorder—Pamidronate—Paget's disease of bone	0.00298	0.00301	CcSEcCtD
Erlotinib—Infection—Alendronate—Paget's disease of bone	0.00295	0.00298	CcSEcCtD
Erlotinib—Mental disorder—Risedronate—Paget's disease of bone	0.00294	0.00297	CcSEcCtD
Erlotinib—Malnutrition—Risedronate—Paget's disease of bone	0.00292	0.00295	CcSEcCtD
Erlotinib—Flatulence—Risedronate—Paget's disease of bone	0.00288	0.00291	CcSEcCtD
Erlotinib—Urinary tract disorder—Zoledronate—Paget's disease of bone	0.00288	0.00291	CcSEcCtD
Erlotinib—Mediastinal disorder—Pamidronate—Paget's disease of bone	0.00288	0.00291	CcSEcCtD
Erlotinib—Connective tissue disorder—Zoledronate—Paget's disease of bone	0.00287	0.00289	CcSEcCtD
Erlotinib—Chills—Pamidronate—Paget's disease of bone	0.00286	0.00289	CcSEcCtD
Erlotinib—Urethral disorder—Zoledronate—Paget's disease of bone	0.00286	0.00289	CcSEcCtD
Erlotinib—Gastrointestinal pain—Etidronic acid—Paget's disease of bone	0.00285	0.00288	CcSEcCtD
Erlotinib—Back pain—Risedronate—Paget's disease of bone	0.00283	0.00286	CcSEcCtD
Erlotinib—Alopecia—Pamidronate—Paget's disease of bone	0.00282	0.00285	CcSEcCtD
Erlotinib—Erythema—Pamidronate—Paget's disease of bone	0.00278	0.00281	CcSEcCtD
Erlotinib—Malnutrition—Pamidronate—Paget's disease of bone	0.00278	0.00281	CcSEcCtD
Erlotinib—Abdominal pain—Etidronic acid—Paget's disease of bone	0.00276	0.00279	CcSEcCtD
Erlotinib—Eye disorder—Zoledronate—Paget's disease of bone	0.00272	0.00275	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Alendronate—Paget's disease of bone	0.00271	0.00274	CcSEcCtD
Erlotinib—Back pain—Pamidronate—Paget's disease of bone	0.00269	0.00271	CcSEcCtD
Erlotinib—Mediastinal disorder—Zoledronate—Paget's disease of bone	0.00263	0.00265	CcSEcCtD
Erlotinib—Syncope—Risedronate—Paget's disease of bone	0.00262	0.00265	CcSEcCtD
Erlotinib—Dyspepsia—Alendronate—Paget's disease of bone	0.00262	0.00264	CcSEcCtD
Erlotinib—Chills—Zoledronate—Paget's disease of bone	0.00262	0.00264	CcSEcCtD
Erlotinib—Arrhythmia—Zoledronate—Paget's disease of bone	0.0026	0.00263	CcSEcCtD
Erlotinib—Alopecia—Zoledronate—Paget's disease of bone	0.00258	0.0026	CcSEcCtD
Erlotinib—Loss of consciousness—Risedronate—Paget's disease of bone	0.00257	0.0026	CcSEcCtD
Erlotinib—Mental disorder—Zoledronate—Paget's disease of bone	0.00255	0.00258	CcSEcCtD
Erlotinib—Cough—Risedronate—Paget's disease of bone	0.00255	0.00258	CcSEcCtD
Erlotinib—Constipation—Alendronate—Paget's disease of bone	0.00254	0.00257	CcSEcCtD
Erlotinib—Pain—Alendronate—Paget's disease of bone	0.00254	0.00257	CcSEcCtD
Erlotinib—Malnutrition—Zoledronate—Paget's disease of bone	0.00254	0.00256	CcSEcCtD
Erlotinib—Erythema—Zoledronate—Paget's disease of bone	0.00254	0.00256	CcSEcCtD
Erlotinib—Syncope—Pamidronate—Paget's disease of bone	0.00249	0.00252	CcSEcCtD
Erlotinib—Myalgia—Risedronate—Paget's disease of bone	0.00249	0.00251	CcSEcCtD
Erlotinib—Arthralgia—Risedronate—Paget's disease of bone	0.00249	0.00251	CcSEcCtD
Erlotinib—Chest pain—Risedronate—Paget's disease of bone	0.00249	0.00251	CcSEcCtD
Erlotinib—Anxiety—Risedronate—Paget's disease of bone	0.00248	0.00251	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Risedronate—Paget's disease of bone	0.00247	0.0025	CcSEcCtD
Erlotinib—Pruritus—Etidronic acid—Paget's disease of bone	0.00247	0.00249	CcSEcCtD
Erlotinib—Back pain—Zoledronate—Paget's disease of bone	0.00246	0.00248	CcSEcCtD
Erlotinib—Loss of consciousness—Pamidronate—Paget's disease of bone	0.00244	0.00247	CcSEcCtD
Erlotinib—Gastrointestinal pain—Alendronate—Paget's disease of bone	0.00243	0.00246	CcSEcCtD
Erlotinib—Cough—Pamidronate—Paget's disease of bone	0.00242	0.00245	CcSEcCtD
Erlotinib—Diarrhoea—Etidronic acid—Paget's disease of bone	0.00239	0.00241	CcSEcCtD
Erlotinib—Infection—Risedronate—Paget's disease of bone	0.00237	0.00239	CcSEcCtD
Erlotinib—Arthralgia—Pamidronate—Paget's disease of bone	0.00237	0.00239	CcSEcCtD
Erlotinib—Myalgia—Pamidronate—Paget's disease of bone	0.00237	0.00239	CcSEcCtD
Erlotinib—Anxiety—Pamidronate—Paget's disease of bone	0.00236	0.00238	CcSEcCtD
Erlotinib—Body temperature increased—Alendronate—Paget's disease of bone	0.00235	0.00237	CcSEcCtD
Erlotinib—Abdominal pain—Alendronate—Paget's disease of bone	0.00235	0.00237	CcSEcCtD
Erlotinib—Shock—Risedronate—Paget's disease of bone	0.00235	0.00237	CcSEcCtD
Erlotinib—Nervous system disorder—Risedronate—Paget's disease of bone	0.00234	0.00236	CcSEcCtD
Erlotinib—Skin disorder—Risedronate—Paget's disease of bone	0.00232	0.00234	CcSEcCtD
Erlotinib—Syncope—Zoledronate—Paget's disease of bone	0.00228	0.0023	CcSEcCtD
Erlotinib—Oedema—Pamidronate—Paget's disease of bone	0.00227	0.00229	CcSEcCtD
Erlotinib—Infection—Pamidronate—Paget's disease of bone	0.00225	0.00228	CcSEcCtD
Erlotinib—Shock—Pamidronate—Paget's disease of bone	0.00223	0.00225	CcSEcCtD
Erlotinib—Loss of consciousness—Zoledronate—Paget's disease of bone	0.00223	0.00225	CcSEcCtD
Erlotinib—Nervous system disorder—Pamidronate—Paget's disease of bone	0.00222	0.00225	CcSEcCtD
Erlotinib—Thrombocytopenia—Pamidronate—Paget's disease of bone	0.00222	0.00224	CcSEcCtD
Erlotinib—Vomiting—Etidronic acid—Paget's disease of bone	0.00222	0.00224	CcSEcCtD
Erlotinib—Cough—Zoledronate—Paget's disease of bone	0.00221	0.00224	CcSEcCtD
Erlotinib—Rash—Etidronic acid—Paget's disease of bone	0.0022	0.00222	CcSEcCtD
Erlotinib—Dermatitis—Etidronic acid—Paget's disease of bone	0.0022	0.00222	CcSEcCtD
Erlotinib—Headache—Etidronic acid—Paget's disease of bone	0.00219	0.00221	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Risedronate—Paget's disease of bone	0.00217	0.0022	CcSEcCtD
Erlotinib—Anorexia—Pamidronate—Paget's disease of bone	0.00216	0.00218	CcSEcCtD
Erlotinib—Chest pain—Zoledronate—Paget's disease of bone	0.00216	0.00218	CcSEcCtD
Erlotinib—Myalgia—Zoledronate—Paget's disease of bone	0.00216	0.00218	CcSEcCtD
Erlotinib—Arthralgia—Zoledronate—Paget's disease of bone	0.00216	0.00218	CcSEcCtD
Erlotinib—Insomnia—Risedronate—Paget's disease of bone	0.00216	0.00218	CcSEcCtD
Erlotinib—Anxiety—Zoledronate—Paget's disease of bone	0.00215	0.00218	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—Paget's disease of bone	0.00215	0.00217	CcSEcCtD
Erlotinib—Asthenia—Alendronate—Paget's disease of bone	0.00213	0.00215	CcSEcCtD
Erlotinib—Dyspnoea—Risedronate—Paget's disease of bone	0.00213	0.00215	CcSEcCtD
Erlotinib—Pruritus—Alendronate—Paget's disease of bone	0.0021	0.00212	CcSEcCtD
Erlotinib—Dyspepsia—Risedronate—Paget's disease of bone	0.0021	0.00212	CcSEcCtD
Erlotinib—Nausea—Etidronic acid—Paget's disease of bone	0.00207	0.00209	CcSEcCtD
Erlotinib—Oedema—Zoledronate—Paget's disease of bone	0.00207	0.00209	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Pamidronate—Paget's disease of bone	0.00207	0.00209	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Risedronate—Paget's disease of bone	0.00206	0.00208	CcSEcCtD
Erlotinib—Infection—Zoledronate—Paget's disease of bone	0.00206	0.00208	CcSEcCtD
Erlotinib—Fatigue—Risedronate—Paget's disease of bone	0.00206	0.00208	CcSEcCtD
Erlotinib—Insomnia—Pamidronate—Paget's disease of bone	0.00205	0.00207	CcSEcCtD
Erlotinib—Pain—Risedronate—Paget's disease of bone	0.00204	0.00206	CcSEcCtD
Erlotinib—Constipation—Risedronate—Paget's disease of bone	0.00204	0.00206	CcSEcCtD
Erlotinib—Shock—Zoledronate—Paget's disease of bone	0.00204	0.00206	CcSEcCtD
Erlotinib—Diarrhoea—Alendronate—Paget's disease of bone	0.00203	0.00205	CcSEcCtD
Erlotinib—Nervous system disorder—Zoledronate—Paget's disease of bone	0.00203	0.00205	CcSEcCtD
Erlotinib—Thrombocytopenia—Zoledronate—Paget's disease of bone	0.00203	0.00205	CcSEcCtD
Erlotinib—Dyspnoea—Pamidronate—Paget's disease of bone	0.00202	0.00204	CcSEcCtD
Erlotinib—Skin disorder—Zoledronate—Paget's disease of bone	0.00201	0.00203	CcSEcCtD
Erlotinib—Dyspepsia—Pamidronate—Paget's disease of bone	0.002	0.00202	CcSEcCtD
Erlotinib—Anorexia—Zoledronate—Paget's disease of bone	0.00197	0.00199	CcSEcCtD
Erlotinib—Decreased appetite—Pamidronate—Paget's disease of bone	0.00197	0.00199	CcSEcCtD
Erlotinib—Dizziness—Alendronate—Paget's disease of bone	0.00197	0.00199	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Pamidronate—Paget's disease of bone	0.00196	0.00198	CcSEcCtD
Erlotinib—Fatigue—Pamidronate—Paget's disease of bone	0.00196	0.00197	CcSEcCtD
Erlotinib—Gastrointestinal pain—Risedronate—Paget's disease of bone	0.00195	0.00197	CcSEcCtD
Erlotinib—Constipation—Pamidronate—Paget's disease of bone	0.00194	0.00196	CcSEcCtD
Erlotinib—Pain—Pamidronate—Paget's disease of bone	0.00194	0.00196	CcSEcCtD
Erlotinib—Vomiting—Alendronate—Paget's disease of bone	0.00189	0.00191	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Zoledronate—Paget's disease of bone	0.00189	0.00191	CcSEcCtD
Erlotinib—Abdominal pain—Risedronate—Paget's disease of bone	0.00189	0.0019	CcSEcCtD
Erlotinib—Body temperature increased—Risedronate—Paget's disease of bone	0.00189	0.0019	CcSEcCtD
Erlotinib—Rash—Alendronate—Paget's disease of bone	0.00187	0.00189	CcSEcCtD
Erlotinib—Insomnia—Zoledronate—Paget's disease of bone	0.00187	0.00189	CcSEcCtD
Erlotinib—Dermatitis—Alendronate—Paget's disease of bone	0.00187	0.00189	CcSEcCtD
Erlotinib—Headache—Alendronate—Paget's disease of bone	0.00186	0.00188	CcSEcCtD
Erlotinib—Gastrointestinal pain—Pamidronate—Paget's disease of bone	0.00185	0.00187	CcSEcCtD
Erlotinib—Dyspnoea—Zoledronate—Paget's disease of bone	0.00185	0.00187	CcSEcCtD
Erlotinib—Dyspepsia—Zoledronate—Paget's disease of bone	0.00182	0.00184	CcSEcCtD
Erlotinib—Decreased appetite—Zoledronate—Paget's disease of bone	0.0018	0.00182	CcSEcCtD
Erlotinib—Abdominal pain—Pamidronate—Paget's disease of bone	0.00179	0.00181	CcSEcCtD
Erlotinib—Body temperature increased—Pamidronate—Paget's disease of bone	0.00179	0.00181	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Zoledronate—Paget's disease of bone	0.00179	0.00181	CcSEcCtD
Erlotinib—Fatigue—Zoledronate—Paget's disease of bone	0.00179	0.0018	CcSEcCtD
Erlotinib—Constipation—Zoledronate—Paget's disease of bone	0.00177	0.00179	CcSEcCtD
Erlotinib—Pain—Zoledronate—Paget's disease of bone	0.00177	0.00179	CcSEcCtD
Erlotinib—Nausea—Alendronate—Paget's disease of bone	0.00177	0.00178	CcSEcCtD
Erlotinib—Asthenia—Risedronate—Paget's disease of bone	0.00171	0.00173	CcSEcCtD
Erlotinib—Gastrointestinal pain—Zoledronate—Paget's disease of bone	0.00169	0.00171	CcSEcCtD
Erlotinib—Pruritus—Risedronate—Paget's disease of bone	0.00169	0.0017	CcSEcCtD
Erlotinib—Abdominal pain—Zoledronate—Paget's disease of bone	0.00164	0.00165	CcSEcCtD
Erlotinib—Body temperature increased—Zoledronate—Paget's disease of bone	0.00164	0.00165	CcSEcCtD
Erlotinib—Diarrhoea—Risedronate—Paget's disease of bone	0.00163	0.00165	CcSEcCtD
Erlotinib—Asthenia—Pamidronate—Paget's disease of bone	0.00163	0.00164	CcSEcCtD
Erlotinib—Pruritus—Pamidronate—Paget's disease of bone	0.0016	0.00162	CcSEcCtD
Erlotinib—Dizziness—Risedronate—Paget's disease of bone	0.00158	0.00159	CcSEcCtD
Erlotinib—Diarrhoea—Pamidronate—Paget's disease of bone	0.00155	0.00157	CcSEcCtD
Erlotinib—Vomiting—Risedronate—Paget's disease of bone	0.00152	0.00153	CcSEcCtD
Erlotinib—Rash—Risedronate—Paget's disease of bone	0.0015	0.00152	CcSEcCtD
Erlotinib—Dermatitis—Risedronate—Paget's disease of bone	0.0015	0.00152	CcSEcCtD
Erlotinib—Dizziness—Pamidronate—Paget's disease of bone	0.0015	0.00151	CcSEcCtD
Erlotinib—Headache—Risedronate—Paget's disease of bone	0.00149	0.00151	CcSEcCtD
Erlotinib—Asthenia—Zoledronate—Paget's disease of bone	0.00149	0.0015	CcSEcCtD
Erlotinib—Pruritus—Zoledronate—Paget's disease of bone	0.00147	0.00148	CcSEcCtD
Erlotinib—Vomiting—Pamidronate—Paget's disease of bone	0.00144	0.00146	CcSEcCtD
Erlotinib—Rash—Pamidronate—Paget's disease of bone	0.00143	0.00144	CcSEcCtD
Erlotinib—Dermatitis—Pamidronate—Paget's disease of bone	0.00143	0.00144	CcSEcCtD
Erlotinib—Headache—Pamidronate—Paget's disease of bone	0.00142	0.00144	CcSEcCtD
Erlotinib—Diarrhoea—Zoledronate—Paget's disease of bone	0.00142	0.00143	CcSEcCtD
Erlotinib—Nausea—Risedronate—Paget's disease of bone	0.00142	0.00143	CcSEcCtD
Erlotinib—Dizziness—Zoledronate—Paget's disease of bone	0.00137	0.00138	CcSEcCtD
Erlotinib—Nausea—Pamidronate—Paget's disease of bone	0.00135	0.00136	CcSEcCtD
Erlotinib—Vomiting—Zoledronate—Paget's disease of bone	0.00132	0.00133	CcSEcCtD
Erlotinib—Rash—Zoledronate—Paget's disease of bone	0.00131	0.00132	CcSEcCtD
Erlotinib—Dermatitis—Zoledronate—Paget's disease of bone	0.0013	0.00132	CcSEcCtD
Erlotinib—Headache—Zoledronate—Paget's disease of bone	0.0013	0.00131	CcSEcCtD
Erlotinib—Nausea—Zoledronate—Paget's disease of bone	0.00123	0.00124	CcSEcCtD
Erlotinib—JAK3—Interleukin receptor SHC signaling—INPP5D—Paget's disease of bone	0.000772	0.0773	CbGpPWpGaD
Erlotinib—JAK3—Signaling events mediated by TCPTP—CSF1—Paget's disease of bone	0.000765	0.0767	CbGpPWpGaD
Erlotinib—JAK3—Interleukin-3, 5 and GM-CSF signaling—INPP5D—Paget's disease of bone	0.000537	0.0539	CbGpPWpGaD
Erlotinib—JAK3—Interleukin-2 signaling—INPP5D—Paget's disease of bone	0.00051	0.0511	CbGpPWpGaD
Erlotinib—JAK3—IL-4 Signaling Pathway—INPP5D—Paget's disease of bone	0.000456	0.0457	CbGpPWpGaD
Erlotinib—JAK3—IL4-mediated signaling events—INPP5D—Paget's disease of bone	0.000408	0.0409	CbGpPWpGaD
Erlotinib—EGFR—Signaling events mediated by TCPTP—CSF1—Paget's disease of bone	0.000335	0.0335	CbGpPWpGaD
Erlotinib—EGFR—Signaling events mediated by PTP1B—CSF1—Paget's disease of bone	0.000271	0.0272	CbGpPWpGaD
Erlotinib—JAK3—Signaling by Interleukins—INPP5D—Paget's disease of bone	0.000262	0.0263	CbGpPWpGaD
Erlotinib—ABL1—Validated transcriptional targets of TAp63 isoforms—PML—Paget's disease of bone	0.000242	0.0243	CbGpPWpGaD
Erlotinib—JAK3—Signaling by Interleukins—SQSTM1—Paget's disease of bone	0.000235	0.0235	CbGpPWpGaD
Erlotinib—ABL1—Apoptosis-related network due to altered Notch3 in ovarian cancer—SQSTM1—Paget's disease of bone	0.000213	0.0213	CbGpPWpGaD
Erlotinib—ABL1—Regulation of retinoblastoma protein—BGLAP—Paget's disease of bone	0.000207	0.0208	CbGpPWpGaD
Erlotinib—ABL1—DNA Damage Response—PML—Paget's disease of bone	0.000201	0.0202	CbGpPWpGaD
Erlotinib—ABL1—miRNA Regulation of DNA Damage Response—PML—Paget's disease of bone	0.000194	0.0195	CbGpPWpGaD
Erlotinib—EGFR—AGE/RAGE pathway—ALPL—Paget's disease of bone	0.000191	0.0192	CbGpPWpGaD
Erlotinib—MAP2K5—BDNF signaling pathway—ALPL—Paget's disease of bone	0.000191	0.0192	CbGpPWpGaD
Erlotinib—ABL1—Neurotrophic factor-mediated Trk receptor signaling—SQSTM1—Paget's disease of bone	0.00019	0.019	CbGpPWpGaD
Erlotinib—ABL1—p73 transcription factor network—PML—Paget's disease of bone	0.000179	0.0179	CbGpPWpGaD
Erlotinib—MAP2K5—EGF/EGFR Signaling Pathway—INPP5D—Paget's disease of bone	0.000154	0.0155	CbGpPWpGaD
Erlotinib—MAP2K5—BDNF signaling pathway—SQSTM1—Paget's disease of bone	0.000152	0.0152	CbGpPWpGaD
Erlotinib—JAK3—Cytokine Signaling in Immune system—NUP205—Paget's disease of bone	0.000143	0.0144	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—CSF1—Paget's disease of bone	0.000129	0.0129	CbGpPWpGaD
Erlotinib—SLCO2B1—SLC-mediated transmembrane transport—NUP205—Paget's disease of bone	0.000128	0.0128	CbGpPWpGaD
Erlotinib—JAK3—Cytokine Signaling in Immune system—PML—Paget's disease of bone	0.000127	0.0127	CbGpPWpGaD
Erlotinib—JAK3—Cytokine Signaling in Immune system—INPP5D—Paget's disease of bone	0.000122	0.0123	CbGpPWpGaD
Erlotinib—JAK3—Cytokine Signaling in Immune system—SQSTM1—Paget's disease of bone	0.00011	0.011	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—PML—Paget's disease of bone	0.000106	0.0107	CbGpPWpGaD
Erlotinib—ABL1—EGF/EGFR Signaling Pathway—INPP5D—Paget's disease of bone	9.7e-05	0.00972	CbGpPWpGaD
Erlotinib—EGFR—Direct p53 effectors—PML—Paget's disease of bone	9.65e-05	0.00967	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—PML—Paget's disease of bone	9.09e-05	0.00911	CbGpPWpGaD
Erlotinib—UGT1A1—NRF2 pathway—SQSTM1—Paget's disease of bone	8.88e-05	0.0089	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—PML—Paget's disease of bone	8.81e-05	0.00883	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—SQSTM1—Paget's disease of bone	8.79e-05	0.0088	CbGpPWpGaD
Erlotinib—EGFR—EGF/EGFR Signaling Pathway—INPP5D—Paget's disease of bone	8.29e-05	0.0083	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—INPP5D—Paget's disease of bone	7.62e-05	0.00763	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—PML—Paget's disease of bone	7.53e-05	0.00754	CbGpPWpGaD
Erlotinib—MKNK1—Disease—VCP—Paget's disease of bone	7.5e-05	0.00752	CbGpPWpGaD
Erlotinib—SLCO2B1—Transmembrane transport of small molecules—NUP205—Paget's disease of bone	6.5e-05	0.00651	CbGpPWpGaD
Erlotinib—MKNK1—Disease—NUP205—Paget's disease of bone	5.73e-05	0.00575	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—NUP205—Paget's disease of bone	5.48e-05	0.00549	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—VCP—Paget's disease of bone	5.25e-05	0.00527	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—SQSTM1—Paget's disease of bone	4.71e-05	0.00472	CbGpPWpGaD
Erlotinib—JAK3—Immune System—NUP205—Paget's disease of bone	4.68e-05	0.00469	CbGpPWpGaD
Erlotinib—MKNK1—Disease—CALCA—Paget's disease of bone	4.26e-05	0.00427	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—CALCA—Paget's disease of bone	4.19e-05	0.0042	CbGpPWpGaD
Erlotinib—JAK3—Immune System—PML—Paget's disease of bone	4.14e-05	0.00415	CbGpPWpGaD
Erlotinib—JAK3—Immune System—INPP5D—Paget's disease of bone	3.99e-05	0.004	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—VCP—Paget's disease of bone	3.96e-05	0.00397	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—INPP5D—Paget's disease of bone	3.9e-05	0.00391	CbGpPWpGaD
Erlotinib—ALB—SLC-mediated transmembrane transport—NUP205—Paget's disease of bone	3.83e-05	0.00384	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—CALCA—Paget's disease of bone	3.81e-05	0.00381	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PML—Paget's disease of bone	3.8e-05	0.00381	CbGpPWpGaD
Erlotinib—JAK3—Immune System—SQSTM1—Paget's disease of bone	3.58e-05	0.00359	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VCP—Paget's disease of bone	3.23e-05	0.00324	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—NUP205—Paget's disease of bone	3.16e-05	0.00316	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—INPP5D—Paget's disease of bone	3.11e-05	0.00312	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—SQSTM1—Paget's disease of bone	3.07e-05	0.00308	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CALCA—Paget's disease of bone	2.98e-05	0.00299	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—INPP5D—Paget's disease of bone	2.88e-05	0.00289	CbGpPWpGaD
Erlotinib—EGFR—Disease—VCP—Paget's disease of bone	2.48e-05	0.00248	CbGpPWpGaD
Erlotinib—ABL1—Immune System—NUP205—Paget's disease of bone	2.4e-05	0.0024	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—SQSTM1—Paget's disease of bone	2.31e-05	0.00232	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CALCA—Paget's disease of bone	2.25e-05	0.00225	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PML—Paget's disease of bone	2.12e-05	0.00212	CbGpPWpGaD
Erlotinib—EGFR—Immune System—NUP205—Paget's disease of bone	2.05e-05	0.00205	CbGpPWpGaD
Erlotinib—ABL1—Immune System—INPP5D—Paget's disease of bone	2.04e-05	0.00205	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—NUP205—Paget's disease of bone	1.95e-05	0.00195	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—INPP5D—Paget's disease of bone	1.92e-05	0.00192	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—INPP5D—Paget's disease of bone	1.92e-05	0.00192	CbGpPWpGaD
Erlotinib—EGFR—Disease—NUP205—Paget's disease of bone	1.89e-05	0.0019	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SQSTM1—Paget's disease of bone	1.89e-05	0.00189	CbGpPWpGaD
Erlotinib—ABL1—Immune System—SQSTM1—Paget's disease of bone	1.83e-05	0.00184	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CALCA—Paget's disease of bone	1.83e-05	0.00184	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PML—Paget's disease of bone	1.81e-05	0.00181	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—INPP5D—Paget's disease of bone	1.76e-05	0.00176	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—INPP5D—Paget's disease of bone	1.75e-05	0.00175	CbGpPWpGaD
Erlotinib—EGFR—Immune System—INPP5D—Paget's disease of bone	1.75e-05	0.00175	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—NUP205—Paget's disease of bone	1.74e-05	0.00175	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VCP—Paget's disease of bone	1.73e-05	0.00174	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—NUP205—Paget's disease of bone	1.71e-05	0.00171	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CALCA—Paget's disease of bone	1.66e-05	0.00167	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—NUP205—Paget's disease of bone	1.63e-05	0.00163	CbGpPWpGaD
Erlotinib—EGFR—Immune System—SQSTM1—Paget's disease of bone	1.57e-05	0.00157	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—INPP5D—Paget's disease of bone	1.49e-05	0.00149	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—NUP205—Paget's disease of bone	1.48e-05	0.00148	CbGpPWpGaD
Erlotinib—EGFR—Disease—CALCA—Paget's disease of bone	1.4e-05	0.00141	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—INPP5D—Paget's disease of bone	1.39e-05	0.00139	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—INPP5D—Paget's disease of bone	1.26e-05	0.00126	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—INPP5D—Paget's disease of bone	1.22e-05	0.00122	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NUP205—Paget's disease of bone	1.06e-05	0.00106	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SQSTM1—Paget's disease of bone	1.01e-05	0.00101	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NUP205—Paget's disease of bone	1e-05	0.001	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CALCA—Paget's disease of bone	9.83e-06	0.000985	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NUP205—Paget's disease of bone	9.18e-06	0.00092	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NUP205—Paget's disease of bone	9.13e-06	0.000915	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—INPP5D—Paget's disease of bone	9.04e-06	0.000905	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—INPP5D—Paget's disease of bone	8.54e-06	0.000855	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NUP205—Paget's disease of bone	8e-06	0.000801	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—INPP5D—Paget's disease of bone	7.83e-06	0.000784	CbGpPWpGaD
Erlotinib—ALB—Metabolism—INPP5D—Paget's disease of bone	7.78e-06	0.00078	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NUP205—Paget's disease of bone	7.54e-06	0.000755	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—INPP5D—Paget's disease of bone	6.82e-06	0.000683	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—INPP5D—Paget's disease of bone	6.43e-06	0.000644	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NUP205—Paget's disease of bone	6.38e-06	0.00064	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—INPP5D—Paget's disease of bone	5.44e-06	0.000545	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NUP205—Paget's disease of bone	4.93e-06	0.000494	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—INPP5D—Paget's disease of bone	4.2e-06	0.000421	CbGpPWpGaD
